Therapeutic Asset Ratings

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Atogepant Episodic Migraine	Stanford University	P4	A (87)
Firazyr Hereditary Angioedema (HAE)	Nang Kuang Pharmaceutical Co., Ltd.	P4	A (87)
fx-1006a ATTR-PN	Qilu Pharmaceutical Co., Ltd.	P4	A (87)
gc1111 Hunter Syndrome	Takeda	P4	A (86)
Turoctocog Alfa Congenital Bleeding Disorder	Novo Nordisk A/S	P4	A (85)
Turoctocog Alfa Haemophilia A	Novo Nordisk A/S	P4	A (85)
Eptacog Alfa Haemophilia A With Inhibitors	AryoGen Pharmed Co.	P4	A (84)
Factor Ix Haemophilia B	CSL Behring	P4	A (84)
Firazyr Hereditary Angioedema	Nang Kuang Pharmaceutical Co., Ltd.	P4	A (84)
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE) Hepatorenal Syndrome	Noorik Biopharmaceuticals AG	P4	A (84)
Recombinant Alpha-Galactosidase A Fabry Disease	Shire	P4	A (84)
Sebetralstat Hereditary Angioedema	KalVista Pharmaceuticals, Ltd.	P4	A (84)
Velpatasvir Hepatitis C Virus Infection	Peking University People's Hospital	P4	A (84)
Acetylsalicylic Acid Myocardial Infarction	Shanghai CureGene Pharmaceutical Co., Ltd.	P4	A (83)
Agalsidase Beta Fabry Disease	Sanofi	P4	A (83)
Cerezyme Gaucher Disease, Non-Neuronopathic Form	Sanofi	P4	A (83)
Duloxetine Diabetic Neuropathies	Aga Khan University	P4	A (83)
Edoxaban Atrial Fibrillation	National Taiwan University Hospital	P4	A (83)
Lipitor Dyslipidemia	Johns Hopkins University	P4	A (83)
Nicotine Tobacco Use Disorder	Brown University	P4	A (83)
Velaglucerase Alfa Gaucher Disease	Takeda	P4	A (83)
VITAMIN D Vitamin D Deficiency	Yale University	P4	A (83)
Alpha-1-Proteinase Inhibitor Alpha 1-Antitrypsin Deficiency	Grifols Therapeutics LLC	P4	A (82)
Avalglucosidase Alfa Glycogen Storage Disease Type II	Genzyme, a Sanofi Company	P4	A (82)
Cytosin-Arabinosid Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)	Associazione Italiana Ematologia Oncologia Pediatrica	P4	A (82)

Showing 1 to 25 of 63,772 assets

PreviousPage 1 of 2551Next